Scienza e Tecnologia
Biologics Conference 2025 Concludes Successfully, Setting New Benchmarks in Biopharmaceutical Innovation and Collaboration
The event commenced with an inaugural ceremony graced by Chief Guest He was joined by Prof. A. B. Pandit, Vice Chancellor- ICT Mumbai, Program Chairs Dr. Narendra Chirmule, CEO - SymphonyTech and Dr. Dhananjay Patankar , Dr. Rajiv Desai , Senior Technical Advisor for Quality and Regulatory - Indian Pharmaceutical Alliance, Mr. GS Krishnan, President - Association of Biotechnology Led Enterprises and Conference Convener Dr. Ratnesh Jain , Managing Director- Mumbai Biocluster.
As part of its commitment to fostering innovation and entrepreneurship, the conference introduced and the to support and encourage emerging talent in biopharma. A significant highlight was the announcement of the second Dr. K. Anji Reddy Memorial Fellowship for Affordable Biopharmaceuticals, awarded to Dr. Cyrus Poonawalla , Chairman of the Serum Institute of India Pvt. Ltd.
Dr. Rajesh Gokhale delivered an impactful talk on , emphasizing the growing role of biomanufacturing in India's industrialization and the recently launched . He stated,
The conference featured a fireside chat on investment opportunities in India's biopharma sector, moderated by Dr. Ratnesh Jain , with esteemed panelists
A powerful plenary talk followed, delivered by titled 'Catalyzing India's Biomanufacturing Revolution: Lessons from My Entrepreneurial Journey.'
Day 1 focused on key areas such as regulatory policies, mRNA technology, cell therapy, biologics and biosimilars markets, biomanufacturing, and analytical validation. A key highlight was the session on ,' featuring insights from leadership from companies like Shilpa Biologicals, Biocon Biologics, Bharat Serums & Vaccines, Premas Biotech, Yapan Bio, and Lupin. The conference also featured , a platform for biotech startups, and , designed to foster networking between attendees and exhibitors.
Day 2 commenced with the Change Makers Plenary Address on by who introduced , an advanced version of its for economical mAb production for the first time in India . This set an enthusiastic tone for further discussions on cutting-edge advancements in gene therapy, AI-ML integration in biopharma, novel biotherapeutics, and veterinary care.
Closed-door sessions on the rising CDMO ecosystem brought together industry leaders from companies like Aragen Bioscience Inc., Aurigene Pharmaceutical Services, Yapan Bio, Shilpa Biologicals, Veeda Lifesciences, Kemwell Biopharma, and Merck, alongside investment firms such as Kotak Equity and Eight Roads, as well as prominent organizations like IPA, Pharmatech Associates, ThermoFisher Scientific, Sartorius Stedim, THSTI, U.S.-India Business Council and CSIR-IGIB.
Throughout the two days, over 70 poster presentations showcased innovative research from academia, startups, CROs, and industry participants. The event concluded on a high note with poster presentation winners receiving INR 25,000 cash prizes, along with awards recognizing the most interactive exhibitors and best exhibitors.
Reflecting on the success of the event, organizers emphasized their mission to expand the Biologics Conference into an even larger platform for collaboration and knowledge exchange. "The overwhelming response from industry leaders, innovators, and entrepreneurs reinforces our vision to make India a global hub for biopharmaceuticals," they stated.
The success of Biologics Conference 2025 marks a new milestone in advancing India's biopharma ecosystem, promising even greater opportunities in the future.
The organizers envision establishing , by curating interactive forums facilitating impactful discussions among key stakeholders, to strengthen the nation's bioeconomy and accelerate advancements in biopharmaceutical research. With each edition, the conference aims to push the boundaries of scientific excellence and industry growth, shaping the future of biopharmaceuticals in India and beyond.
Website: https://biologicsworkshop.com/
Mumbai Biocluster is a leading innovation hub in ICT
Mumbai, India , driving biopharmaceutical R&D and supporting the transition of early-stage innovations into clinical-stage biotech companies. With cutting-edge infrastructure and global collaborations, it tackles critical health challenges, including rare diseases and advanced therapies. Committed to sustainable growth, Mumbai Biocluster empowers startups, academia, and MSMEs through R&D, clinical-stage manufacturing, and regulatory support.
For more information, visit Mumbai Biocluster.
Photo: https://mma.prnewswire.com/media/2619755/Biologics_Conference_2025.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/biologics-conference-2025-concludes-successfully-setting-new-benchmarks-in-biopharmaceutical-innovation-and-collaboration-302376292.html